Stay updated on Nivolumab in Refractory Biliary Tract Cancers Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page.

Latest updates to the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page
- Check6 days agoChange DetectedFooter revision updated: added Revision: v3.4.2 and removed Revision: v3.4.1.SummaryDifference0.1%

- Check13 days agoChange DetectedRevision tag updated from v3.4.0 to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedAdded a 'Show glossary' toggle and updated the page revision header (Revision: v3.4.0), with minor capitalization tweaks to QC-related labels and FEAR Act wording.SummaryDifference0.2%

- Check35 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed.SummaryDifference0.1%

- Check56 days agoChange DetectedAdded study locations in California, Florida, and Georgia. Updated page to revision v3.3.3 on 2025-12-22.SummaryDifference0.7%

- Check84 days agoChange DetectedThese changes update the Publications section to say publications are automatically filled from PubMed, and update the page revision to v3.3.2. They do not affect the study data, eligibility criteria, or locations.SummaryDifference0.1%

Stay in the know with updates to Nivolumab in Refractory Biliary Tract Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Refractory Biliary Tract Cancers Clinical Trial page.